CD-5 Immunohistochemistry Test at Lahore PCR Lab

CD-5 Immunohistochemistry at Lahore PCR Lab

CD-5 (Cluster of Differentiation 5) Immunohistochemistry (IHC) is a highly specialized pathology laboratory investigation used to identify the presence of the CD5 protein on the surface of cells within tissue samples. At Lahore PCR Lab, located in Lahore, Pakistan, this diagnostic test is performed with precision to assist in the accurate classification of various hematologic malignancies and other neoplastic conditions. Immunohistochemistry combines anatomical, immunological, and biochemical techniques to visualize specific cellular components under a microscope. By utilizing monoclonal antibodies directed against the CD5 antigen, pathologists can identify cell lineages, differentiate between benign and malignant proliferations, and formulate highly specific diagnostic reports.

The CD5 antigen is a 67 kDa single-chain transmembrane glycoprotein. It is classically expressed on the surface of mature T-lymphocytes and a small, specialized subpopulation of mature B-lymphocytes known as B-1a cells. In normal lymphoid tissues, CD5-positive T-cells are found predominantly in the paracortical areas of lymph nodes and the periarteriolar lymphoid sheaths of the spleen. However, the primary clinical utility of CD-5 Immunohistochemistry lies in its ability to detect aberrant CD5 expression in B-cell neoplasms. In normal physiological states, the vast majority of peripheral B-lymphocytes are CD5-negative. When B-cell malignancies express this marker, it serves as a critical diagnostic clue that narrows down the differential diagnosis significantly, particularly pointing toward Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) or Mantle Cell Lymphoma (MCL).

At Lahore PCR Lab, the CD-5 IHC test is performed on formalin-fixed, paraffin-embedded (FFPE) tissue sections. These sections are typically obtained from surgical biopsies of lymph nodes, bone marrow trephines, spleen, or other extranodal tissues. The diagnostic value of this test is immense, as it allows for the subclassification of small B-cell lymphomas, which have vastly different prognoses and treatment protocols. By integrating CD-5 IHC into a comprehensive immunohistochemical panel—alongside other markers such as CD19, CD20, CD23, Cyclin D1, and SOX11—our consultant pathologists in Lahore can deliver highly accurate diagnoses that guide oncologists in planning targeted therapies, monitoring disease progression, and predicting clinical outcomes.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-5 Immunohistochemistry is a laboratory test performed on a tissue specimen (biopsy), there is no direct preparation required for the laboratory test itself. However, the preparation depends entirely on the surgical procedure used to obtain the tissue sample. Patients should follow these general guidelines prior to their biopsy procedure:

• Consultation Regarding Medications: Inform your physician about all medications you are currently taking, especially blood thinners such as aspirin, clopidogrel, warfarin, or direct oral anticoagulants, as these may need to be temporarily discontinued before a biopsy.
• Fasting Requirements: If the biopsy is to be performed under conscious sedation or general anesthesia, you will be instructed to fast (nil by mouth) for 6 to 8 hours prior to the procedure. Local anesthesia typically does not require fasting.
• Medical History Disclosure: Provide a complete medical history to the clinical team, including any known allergies to local anesthetics, antiseptics, or latex.
• Post-Procedure Arrangements: Arrange for a family member or friend to drive you home after the biopsy, especially if sedative medications are administered.
• Wear Comfortable Clothing: On the day of the biopsy, wear loose, comfortable clothing that allows easy access to the site being biopsied.

During the Procedure

The clinical procedure is divided into two distinct phases: the collection of the tissue specimen and the subsequent laboratory analysis at Lahore PCR Lab.

• Specimen Collection: A qualified surgeon or radiologist performs the biopsy (e.g., core needle biopsy, excisional lymph node biopsy, or bone marrow aspiration and trephine biopsy) under sterile conditions. Local or general anesthesia is used to ensure patient comfort.
• Tissue Fixation: Immediately after removal, the tissue specimen is placed in a container filled with 10% neutral buffered formalin. This step is critical to preserve the cellular architecture and prevent autolysis.
• Laboratory Processing: At Lahore PCR Lab, the tissue undergoes processing where water is removed and replaced with paraffin wax. The tissue is then embedded into a paraffin block.
• Microtome Sectioning: Extremely thin sections (typically 3 to 5 microns thick) are cut from the paraffin block using a precision microtome and mounted onto glass slides.
• Antigen Retrieval: The slides are heated and treated with specific buffer solutions to unmask the CD5 antigen epitopes that may have been cross-linked during formalin fixation.
• Antibody Incubation: The tissue sections are incubated with primary monoclonal antibodies directed specifically against the CD5 antigen.
• Detection and Visualization: A secondary antibody conjugated with an enzyme (such as horseradish peroxidase) is applied, followed by a chromogen substrate (usually diaminobenzidine, or DAB). This chemical reaction produces a visible brown precipitate at the site of CD5 antigen-antibody binding.
• Microscopic Evaluation: A Consultant Pathologist examines the stained slides under a high-resolution microscope to evaluate the intensity, pattern, and cellular distribution of the CD5 staining.

When is a CD-5 Immunohistochemistry Performed?

Evaluation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are biologically identical neoplasms characterized by the accumulation of monoclonal, immunologically dysfunctional small B-lymphocytes. Physicians frequently request CD-5 Immunohistochemistry at Lahore PCR Lab when a patient presents with persistent lymphocytosis, generalized lymphadenopathy, or splenomegaly. In these conditions, the neoplastic B-cells aberrantly express the CD5 marker on their surface. Demonstrating CD5 positivity on B-cells (which are also identified by CD19 and CD20 positivity) is a diagnostic cornerstone. The pathologist uses this finding to confirm CLL/SLL and rule out other non-neoplastic reactive lymphocytoses or CD5-negative B-cell lymphomas, ensuring the patient receives the correct therapeutic regimen.

Diagnosis and Differentiation of Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma that clinically and morphologically overlaps with other small B-cell lymphomas. Because MCL carries a significantly different prognosis and requires more intensive therapeutic strategies, its accurate differentiation is critical. CD-5 Immunohistochemistry is routinely performed on lymph node biopsies suspected of harboring MCL, as these neoplastic cells are characteristically CD5-positive. To distinguish MCL from CLL/SLL (which is also CD5-positive), the pathologist evaluates the co-expression of other markers; MCL is typically positive for Cyclin D1 and SOX11 but negative for CD23. This precise immunophenotypic profiling is essential for avoiding misdiagnosis.

Distinguishing Thymic Epithelial Tumors from Other Mediastinal Neoplasms

Mediastinal masses present a significant diagnostic challenge due to the wide variety of potential tumors in this region, including thymomas, thymic carcinomas, lymphomas, and germ cell tumors. CD-5 Immunohistochemistry plays a vital role in this differential diagnosis. While normal thymic epithelial cells are CD5-negative, thymic carcinoma cells frequently show strong, diffuse CD5 expression. Conversely, other carcinomas, such as lung adenocarcinomas that may metastasize to the mediastinum, are almost universally CD5-negative. Performing CD-5 IHC on mediastinal core biopsies helps pathologists at Lahore PCR Lab confidently identify primary thymic epithelial malignancies and guide appropriate surgical and oncological planning.

Investigation of Unexplained Lymphadenopathy and Splenomegaly

Persistent, unexplained enlargement of the lymph nodes (lymphadenopathy) or spleen (splenomegaly) warrants a thorough histopathological investigation to rule out malignancy. When a biopsy is performed, CD-5 Immunohistochemistry is included in the initial screening panel. This allows the pathologist to map the distribution of T-cells and B-cells within the tissue. In benign, reactive lymph nodes, CD5 staining clearly delineates the T-cell zones (paracortex) and highlights the normal, scattered T-cells within germinal centers. Any disruption of this normal architectural pattern, or the presence of sheets of CD5-positive B-cells, immediately alerts the pathologist to the presence of a lymphoproliferative disorder, prompting further subtyping.

Monitoring of Minimal Residual Disease and Phenotypic Shift

In patients undergoing treatment for CD5-positive hematologic malignancies, follow-up biopsies of the bone marrow or lymph nodes may be performed to assess therapeutic response. CD-5 Immunohistochemistry is utilized to detect minimal residual disease (MRD) by identifying small, persistent clusters of aberrant CD5-positive B-cells that may not be easily visible on routine hematoxylin and eosin (H&E) stains. Additionally, some lymphomas can undergo phenotypic shifts or transformation over time (such as Richter's transformation of CLL to diffuse large B-cell lymphoma). Monitoring the CD5 status of the tumor cells over the course of the disease provides critical information regarding clonal evolution and treatment resistance.

What Does a CD-5 Immunohistochemistry Detect?

• Aberrant CD5 Expression on B-Lymphocytes: Confirms the presence of a CD5-positive B-cell neoplasm, most commonly CLL/SLL or Mantle Cell Lymphoma.
• Normal T-Cell Lineage Identification: Highlights mature helper and cytotoxic T-lymphocytes in normal, reactive, or neoplastic tissues.
• Mantle Cell Lymphoma (MCL) Confirmation: Detects strong CD5 positivity in atypical lymphoid cells, which, when combined with Cyclin D1 positivity, confirms MCL.
• Thymic Carcinoma Differentiation: Identifies CD5 expression in epithelial cells of thymic carcinoma, helping differentiate it from lung adenocarcinoma.
• T-Cell Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Detects CD5 expression in immature T-cells, aiding in the diagnosis of precursor T-cell malignancies.
• Peripheral T-Cell Lymphoma (PTCL): Evaluates the presence or aberrant loss of CD5 in mature T-cell neoplasms.
• Aberrant Loss of CD5 in T-Cell Malignancies: Detects a common immunophenotypic abnormality where neoplastic T-cells lose normal CD5 expression.
• Anaplastic Large Cell Lymphoma (ALCL): Assesses CD5 expression levels, which can be variable or lost in these large-cell T-cell neoplasms.
• Diffuse Large B-Cell Lymphoma (DLBCL) CD5+ Subtype: Identifies a de novo CD5-positive subset of DLBCL associated with an aggressive clinical course.
• Follicular Lymphoma Exclusion: Helps rule out Follicular Lymphoma, which is characteristically CD5-negative.
• Marginal Zone Lymphoma (MZL) Differentiation: Aids in distinguishing MZL (typically CD5-negative) from CD5-positive B-cell lymphoproliferative disorders.
• Hairy Cell Leukemia (HCL) Distinction: Confirms CD5 negativity, which is typical for classic Hairy Cell Leukemia.
• Lymphoplasmacytic Lymphoma (LPL) Evaluation: Assists in differentiating LPL (usually CD5-negative) from other small B-cell lymphomas.
• Monoclonal B-Cell Lymphocytosis (MBL): Detects low-level CD5-positive clonal B-cell populations in peripheral blood or marrow.
• Reactive Lymph Node Architecture: Visualizes normal T-cell distribution within the paracortex and interfollicular regions of reactive lymph nodes.
• T-Zone Hyperplasia: Identifies expanded CD5-positive T-cell populations in benign, reactive conditions.
• Thymoma Evaluation: Highlights the abundant, non-neoplastic T-cells (thymocytes) within thymic epithelial tumors.
• Mycosis Fungoides Diagnosis: Evaluates CD5 expression in cutaneous T-cell infiltrates to identify aberrant antigen loss.
• Splenic Marginal Zone Lymphoma (SMZL) Exclusion: Helps differentiate SMZL (usually CD5-negative) from CD5-positive splenic lymphomas.
• B-1a Subset Identification: Identifies the rare, normal physiological subpopulation of CD5-positive B-cells in specific tissue microenvironments.
• Infiltration of Salivary Glands (MALT Lymphoma): Evaluates CD5 status to rule out transformation or secondary involvement by a CD5-positive lymphoma.
• Bone Marrow Involvement: Determines the presence and pattern of CD5-positive lymphoid aggregates within bone marrow biopsy specimens.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that waiting for pathology results can be an anxious time for patients and their families. Because immunohistochemistry requires multiple sequential steps—including tissue processing, paraffin embedding, microtome sectioning, antigen retrieval, antibody incubation, and expert microscopic review—the turnaround time for a CD-5 IHC test is typically 3 to 5 working days from the receipt of the tissue specimen. This timeline ensures that all quality control measures are met and that the slides are thoroughly evaluated by our consultant pathologists.

Once the diagnostic report is finalized, patients and their referring physicians can access the results conveniently. Lahore PCR Lab offers digital report access through our secure online portal, allowing you to view and download your reports from the comfort of your home. Additionally, reports can be sent directly via WhatsApp or email, or collected physically from our main laboratory facility in Lahore. We ensure that all reports are structured clearly, containing detailed microscopic descriptions, immunophenotypic findings, and a definitive diagnostic conclusion to guide your clinical team.

CD-5 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Mature T-Lymphocytes	Strong, diffuse membranous CD5 positivity	Loss of CD5 expression (aberrant loss in T-cell lymphomas)
Normal B-Lymphocytes	CD5 negative (except for a tiny B-1a subset)	Aberrant CD5 expression (indicative of B-cell lymphoproliferative disorders)
Lymph Node Paracortex	Rich in CD5-positive T-cells	Effacement of architecture by CD5-positive neoplastic cells
Lymph Node Germinal Centers	Predominantly CD5-negative (B-cells) with scattered CD5-positive T-follicular helper cells	Infiltration by CD5-positive neoplastic B-cells (e.g., CLL/SLL or MCL)
Thymic Epithelial Cells	CD5 negative	CD5 positive (indicative of Thymic Carcinoma)
Neoplastic B-Cells (CLL/SLL)	Not applicable (absent in healthy tissue)	Co-expression of CD5, CD19, CD20, and CD23
Neoplastic B-Cells (Mantle Cell)	Not applicable (absent in healthy tissue)	Co-expression of CD5, CD19, CD20, and Cyclin D1 (CD23 negative)
Bone Marrow Trephine	Interspersed normal CD5-positive T-cells	Clonal aggregates of CD5-positive B-cells indicating marrow involvement

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for CD-5 Immunohistochemistry?

• Experienced healthcare professionals: Our pathology department is led by highly qualified consultant pathologists with extensive experience in immunohistochemistry and molecular diagnostics.
• Patient-focused care: We prioritize patient comfort and clarity, ensuring that all diagnostic processes are handled with utmost empathy and professionalism.
• Quality diagnostic services: Lahore PCR Lab adheres to strict internal and external quality control protocols to ensure the highest accuracy of all immunohistochemical stains.
• Professional reporting: Our diagnostic reports are comprehensive, detailed, and structured to provide oncologists and clinicians with clear, actionable insights.
• Modern diagnostic approach: We utilize advanced automated staining platforms and high-affinity antibodies to minimize background staining and deliver clear, interpretable slides.
• Comfortable environment: Our collection centers and laboratory facilities in Lahore are designed to provide a clean, safe, and welcoming environment for all patients.
• Convenient location: Situated accessibly within Lahore, our laboratory offers easy access for sample drop-offs and patient visits.
• Commitment to accurate diagnosis: We understand the critical nature of cancer diagnostics and are dedicated to providing timely, precise, and reliable results to guide patient management.